

Emerald Clinics Completes Capital Raising and Opens Two Medicinal Cannabis Clinics

- **Emerald has successfully completed a A\$2.5m capital raising supported by leading cannabis companies Canopy Growth Corporation & Cann Group Limited, and US-based cannabis investor CB1 Capital**
- **Emerald medicinal cannabis treatment clinics opened in Sydney & Perth**
- **Emerald continues building a network of clinics across Australia staffed and managed by trained cannabinoid specialists and general practitioners**

Monday, 18 February 2019 – Leading independent medicinal cannabis clinic group, Emerald Clinics (“Emerald” or the “Company”), is pleased to announce that it has successfully completed a A\$2.5 million capital raising, supported by the global leader in cannabis, Canopy Growth Corporation (TSX:WEED), as well as Australia’s leading medicinal cannabis producer, Cann Group Limited (ASX:CAN). The capital raising was also supported by leading US-based specialist cannabis investor, CB1 Capital.

The capital raising was undertaken by means of a redeemable convertible note and follows Emerald’s successful A\$3 million seed raising, undertaken in May 2018, which was supported by Australian fund managers and wholesale investors. All funds raised via both the seed raising and convertible note will be used to support the ongoing national roll-out program of Emerald’s clinics.

Emerald successfully opened its first clinic in Subiaco, Perth in December 2018, and second clinic in Woolloomooloo, Sydney in early February 2019. Emerald will continue expanding the network to other major cities and regional centres throughout 2019 to ensure Australians seeking a regulated supply of medicinal cannabis have access to highly-informed healthcare practitioners.

Emerald’s primary focus is to provide high-quality care and improve clinical outcomes for patients who are seeking to manage conditions such as chronic neuropathic pain. Patients referred to Emerald’s clinics undergo a thorough medical examination to assess their clinical history and suitability for use of medicinal cannabis. If deemed appropriate, the clinician will develop a cannabinoid treatment plan with the patient, who is then monitored in follow-up appointments to ensure the treatment plan achieves desired clinical outcomes. Patient access requires approval from Australia’s national regulatory authority for therapeutic goods, the Therapeutic Goods Administration (TGA), and relevant State authorities.

Emerald’s clinicians prescribe domestic and international cannabis medicines which meet strict certification, quality and continuation of supply requirements. Emerald obtains consent to collect de-identified clinical quality data throughout the course of treatment to inform clinical models and support collaborative research studies and trials with third parties. Emerald and Cann Group plan to collaborate on future clinical studies

Cann Group General Manager of Commercial, Shane Duncan, said, “Cann Group is pleased to establish this relationship with Emerald Clinics. This is a new and developing area of medicine and we see these specialty clinics as playing a vital role in supporting the appropriate use of medicinal cannabis. We also look forward to exploring potential research programs with Emerald Clinics’ doctors, which will contribute to the building of the evidence base supporting the safe and effective use of medicinal cannabis treatments.”





Emerald Clinics

Emerald Clinics
PO Box 95, North Perth, 6906
info@emeraldclinics.com.au
www.emeraldclinics.com.au
1300 436 363

The Emerald team comprises several leading specialists, clinical researchers and experienced healthcare service professionals. The team is advised and led by Dr Danial Schechter and Sir Professor John Tooke. Dr Schechter is the co-founder and medical director of the Canadian Cannabinoid Medical Clinic (CMClinic), one of the largest referral-only clinics in Canada specialising in cannabinoid medicine. Sir John is a non-executive director for Bupa plc, as well as a member of the Independent Review Board for Google DeepMindHealth UK.

PAC Partners acted as sole lead manager for both the seed and convertible note capital raisings and, subject to the achievement of internal Company milestones, regulatory approvals and the production of a prospectus, will seek to assist the Company with a listing in 2019.

For further information, please see www.emeraldclinics.com.au

ENDS

About Emerald Clinics:

Emerald Clinics is a healthcare technology and services company whose mission is to improve lives, by learning from the experience of every patient that is treated with a cannabinoid medicine.

Our team includes specialist physicians, experienced General Practitioners and clinical trials experts to deliver best practice care for patients who have exhausted conventional therapies in Australia.

Contact:

Dr Stewart Washer
Chairman
c: +61 418 288 212
e: stewart.washer@emeraldclinics.com.au

Adam James
Commercial Manager
c: +61 400 105 462
e: adam.james@emeraldclinics.com.au

